ArticleBioscience reports2017
Ratio of matrix metalloproteinase-2 to -9 is a more accurate predictive biomarker in women with suspected pre-eclampsia.
Article in Bioscience reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 17 citations in OpenAlex.
- Urinary phenol and paraben concentrations in association with markers of inflammation during pregnancy in Puerto Rico.The Science of the total environment · 2024Article
- Circulatory Maternal Endothelin 1 and Matrix Metalloproteinase-9 Gene Expression in PREECLAMPSIA: A Study in Western Uttar Pradesh, India.Journal of obstetrics and gynaecology of India · 2023Article
- Expression of Matrix Metalloproteinase-2,-7,-9 in Serum during Pregnancy in Patients with Pre-Eclampsia: A Prospective Study.International journal of environmental research and public health · 2022Article
- New Insights into the Role of Matrix Metalloproteinases in Preeclampsia.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre-eclampsia (PE) is a condition unique to pregnancy, and abnormal expression of matrix metalloproteinases (MMPs) has been implicated in its pathogenesis. We aimed to evaluate the reliability of plasma levels of MMP-2, MMP-9 and their relative ratio in predicting PE. A total of 318 women with suspected PE were recruited for the study, who were subsequently either cleared or diagnosed of PE and grouped accordingly. Their baseline characteristics were compared. Blood samples were also collected from all participants, to determine the plasma levels of MMP-2 and MMP-9. The predictive values of levels of MMP-2 and MMP-9, as well as their ratio, were analyzed using the receiver operating characteristic (ROC) curve. Either MMP-2 or MMP-9 alone did not exhibit any obvious differences between normal and PE pregnancies. However the ratio of MMP-2/MMP-9 was significantly higher in PE-affected pregnancy than normal control group. ROC curve analysis also indicated that the MMP-2/MMP-9 ratio provided better compromise between specificity and sensitivity in distinguishing PE from normal pregnancies, than either of the two MMPs alone. MMP-2/MMP-9 ratio is a more accurate biomarker to predict PE than either MMP-2 or MMP-9 alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.